Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

3.4.23.24: Candidapepsin

This is an abbreviated version!
For detailed information about Candidapepsin, go to the full flat file.

Word Map on EC 3.4.23.24

Reaction

Preferential cleavage at the carboxyl of hydrophobic amino acids, but fails to cleave Leu15-Tyr, Tyr16-Leu and Phe24-Phe of insulin B chain. Activates trypsinogen, and degrades keratin =

Synonyms

Aspartate protease, aspartic protease, aspartic protease 2, aspartic protease Sap2p, aspartic proteinase 3, aspartyl protease, aspartyl protease Sap2p, aspartyl protease Sap4, aspartyl protease Sap5, aspartyl protease Sap6, aspartyl proteinase, candialbicin, Candida albicans aspartic proteinase, Candida albicans carboxyl proteinase, Candida albicans secretory acid proteinase, Candida albicans-secreted aspartic proteinase, Candida olea acid proteinase, Candidapepsin-1, candidapepsin-2, EC 3.4.23.6, EC 3.4.4.17, Proteinase, Candida albicans aspartic, Proteinase, Candida aspartic, Proteinase, Candida olea aspartic, S-aspartyl proteinase, SAP, SAP1, Sap10, SAP11, Sap1p, SAP2, Sap2p, SAP2X, SAP3, Sap3p, SAP4, Sap4p, SAP5, Sap5p, SAP6, Sap6p, Sap7, Sap7p, Sap8, Sap8p, Sap9, Sap9p, SAPP1, Sapp1p, SAPP2, Sapp2p, SAPP3, SAPT1, Sapt1p, SAPT2, SAPT3, SAPT4, secreted aspartic protease, secreted aspartic protease 1, secreted aspartic protease 2, secreted aspartic proteinase, secreted aspartic proteinase 1, secreted aspartic proteinase 2, secreted aspartic proteinase-2, secreted aspartyl peptidase, secreted aspartyl protease, secreted aspartyl protease 9, secreted aspartyl proteinase, secreted aspartyl proteinase 2, secreted aspartyl proteinase 5, secreted aspartyl proteinase2, secreted aspartyl proteinases, secreted aspartyl-type peptidase, secretory aspartyl proteinase, secretory aspartyl proteinase SAP1, secretory aspartyl proteinase SAP2p, secretory aspartyl proteinase SAP3p, secretory aspartyl proteinase SAP4p, secretory aspartyl proteinase SAP5p, secretory aspartyl proteinase SAP6p, yapsin, Yps

ECTree

     3 Hydrolases
         3.4 Acting on peptide bonds (peptidases)
             3.4.23 Aspartic endopeptidases
                3.4.23.24 Candidapepsin

Inhibitors

Inhibitors on EC 3.4.23.24 - Candidapepsin

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1R,5R,7R)-3-benzyl-7-(piperidin-1-ylcarbonyl)-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one
-
74% inhibition at 0.02 mM
(1R,5R,7R)-3-benzyl-N-(2-hydroxyethyl)-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide
-
71% inhibition at 0.02 mM
(1R,5R,7R)-3-benzyl-N-(3-hydroxypropyl)-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide
-
23% inhibition at 0.02 mM
(1R,5R,7R)-3-benzyl-N-[(1R)-2-hydroxy-1-phenylethyl]-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide
-
31% inhibition at 0.02 mM
(1R,5R,7R)-3-benzyl-N-[(2R)-1-hydroxy-3-phenylpropan-2-yl]-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide
-
29% inhibition at 0.02 mM
(1R,5R,7R)-3-benzyl-N-[(2S)-1-hydroxy-3-phenylpropan-2-yl]-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide
-
30% inhibition at 0.02 mM
(1R,5R,7R)-3-benzyl-N-[(2S)-1-hydroxy-4-methylpentan-2-yl]-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide
-
71% inhibition at 0.02 mM
(1R,5R,7R)-3-benzyl-N-[(2S)-1-hydroxypropan-2-yl]-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide
-
35% inhibition at 0.02 mM
(1R,5R,7R)-N-(2-aminoethyl)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide
-
63% inhibition at 0.02 mM
(1R,5S,7R)-3-benzyl-7-(1,4-diazepan-1-ylcarbonyl)-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one
-
63% inhibition at 0.02 mM
(1R,5S,7R)-3-benzyl-7-(morpholin-4-ylcarbonyl)-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one
-
62% inhibition at 0.02 mM
(1R,5S,7R)-3-benzyl-7-(thiomorpholin-4-ylcarbonyl)-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one
-
58% inhibition at 0.02 mM
(1R,5S,7R)-3-benzyl-7-[[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one
-
34% inhibition at 0.02 mM
(1R,5S,7R)-3-benzyl-7-[[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one
-
48% inhibition at 0.02 mM
(1R,5S,7R)-3-benzyl-7-[[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl]-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one
-
58% inhibition at 0.02 mM
(1R,5S,7S)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid [1-hydroxymethyl-3(R)-methylbutyl]amide
-
60% inhibition at 0.02 mM
(1R,5S,7S)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid [1-hydroxymethyl-3(S)-methylbutyl]amide
-
33% inhibition at 0.02 mM
(1S,5R,7R)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid benzyl-(1-hydroxymethyl-3-methylbutyl)amide
-
35% inhibition at 0.02 mM
(1S,5R,7R)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid [1-hydroxymethyl-3(R)-methylbutyl]amide
-
29% inhibition at 0.02 mM
(1S,5S,7S)-3-benzyl-7-(piperidine-1-carbonyl)-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one
-
50% inhibition at 0.02 mM
(2R,3S)-phenylnorstatine
(2S,3S)-phenylnorstatine
(3S,4S)-phenylstatine
(3S,4S)-statine
1,2-epoxy-3-(4-nitrophenoxy)propane
acetyl-Phe-Ile-Phe-psi[OH-OH]-Phe-Glu-Phe-acetyl
-
transition-state peptidomimetic TS-41
acetyl-Trp-Phe-psi[OH-OH]-Phe-Trp-acetyl
-
transition-state peptidomimetic TS-49
acetyl-Trp-Ser-Phe-psi[OH-OH]-Phe-kynurenic acid
-
transition-state peptidomimetic TS-57
acetyl-Trp-Val-Phe-psi[OH-OH]-Phe-Glu-Phe-acetyl
-
transition-state peptidomimetic TS-43
acetyl-Trp-Val-Phe-psi[OH-OH]-Phe-Val-acetyl
-
transition-state peptidomimetic TS-75
acetyl-Trp-Val-Phe-psi[OH-OH]-Phe-Val-Trp-acetyl
-
transition-state peptidomimetic TS-42
amprenavir
-
most effective inhibitor of Sap2, about 92% inhibition at 0.1 mM
antipain
-
partial
Aprotinin
-
-
Arg-Ile-Phe-psi[CH2-NH]-Phe-Gln-Arg
-
transition-state peptidomimetic TS-2
benzyloxycarbonyl-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-OMe
-
benzyloxycarbonyl-L-Val-L-Val-((3R,4R)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-OMe
-
benzyloxycarbonyl-L-Val-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-( (3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-OMe
-
benzyloxycarbonyl-L-Val-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-((3R,4R)-4-amino-3-hydroxy-5-phenylpentanoic acid)-OMe
-
benzyloxycarbonyl-L-Val-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-NH2
-
benzyloxycarbonyl-L-Val-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-OH
-
benzyloxycarbonyl-L-Val-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-OMe
-
benzyloxycarbonyl-L-Val-L-Val-statine-L-Ala-statine-OH
-
Butanedione
-
-
chymostatin
-
-
Diazoacetylnorleucine methyl ester
ethyl 4-[[(1R,5S,7R)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]oct-7-yl]carbonyl]piperazine-1-carboxylate
-
74% inhibition at 0.02 mM
fluconazole
-
-
indinavir
-
-
inhibitor A-70450
-
isovaleryl-Val-Val-statyl-Ala-statyl-OH
-
-
kynurenic acid-Dtg-Phe-psi(S,R,S)[OH]-Phe-dimethylphenoxyacetic acid
-
transition-state peptidomimetic TS-92
kynurenic acid-Dtg-Phe-psi[OH-OH]-Phe-phenoxyacetic acid
-
transition-state peptidomimetic TS-63
kynurenic acid-Thr-Phe-psi(S,R,S)[OH]-Phe-dimethylphenoxyacetic acid
-
transition-state peptidomimetic TS-93
kynurenic acid-Thr-Phe-psi[OH-OH]-Phe-kynurenic acid
-
transition-state peptidomimetic TS-59
kynurenic acid-Val-Phe-psi(S,R,S)[OH]-Phe-dimethylphenoxyacetic acid
-
transition-state peptidomimetic TS-94
kynurenic acid-Val-Phe-psi(S,R,S)[OH]-Phe-Val-kynurenic acid
-
transition-state peptidomimetic TS-91
kynurenic acid-Val-Phe-psi[OH-OH]-Phe-Val-kynurenic acid
-
best inhibitor; transition-state peptidomimetic TS-70
lopinavir
-
-
Lys-Ile-Phe-psi[CH2-NH]-Phe-Gln-Arg
-
transition-state peptidomimetic TS-23
methyl palmitate
-
mycogenic silver nanoparticles
-
nelfinavir
-
-
pepstatin
pepstatin A
phellandrene
-
phenylmethylsulfonyl fluoride
-
ritonavir
saquinavir
SDS
-
tolerated at 0.01% w/v, decrease of activity at 0.1% w/v, 1% completely destroys activity within a few min
t-butoxylcarbonyl-Phe-psi[OH-OH]-Phe-Dtg-phenoxyacetic acid
-
transition-state peptidomimetic TS-54
t-butoxylcarbonyl-Phe-psi[OH-OH]-Phe-Glu-Phe-acetyl
-
transition-state peptidomimetic TS-53
tert-butoxycarbonyl-Val-Val-(3R,4R)-4-amino-3-hydroxy-5-phenylpentanoyl-Ala-phenylstatyl-O-methyl ester
-
-
tert-butoxycarbonyl-Val-Val-phenylstatyl-Ala-(3R,4R)-4-amino-3-hydroxy-5-phenylpentanoyl-OH
-
-
tert-butoxycarbonyl-Val-Val-phenylstatyl-Ala-O-methyl ester
-
-
tert-butoxycarbonyl-Val-Val-phenylstatyl-Ala-phenylstatyl-NH2
-
-
tert-butoxycarbonyl-Val-Val-phenylstatyl-Ala-phenylstatyl-O-methyl ester
-
-
tert-butoxycarbonyl-Val-Val-phenylstatyl-Ala-phenylstatyl-OH
-
-
Tetradecanal
-
Trp-Ile-Phe-psi[CH2-NH]-Phe-Gln-Trp
-
transition-state peptidomimetic TS-10
Xan-Dtg-Val-psi(S,R,S)[OH]-Val-Dtg-Xan
-
transition-state peptidomimetic TS-90
additional information
-